Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.

You may also be interested in...



FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study

Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.

Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line

GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.

Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line

GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS068782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel